# A Study of YL202 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07202364/  
OnCo record `nct07202364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of YL202 in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL202 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07202364 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2025-08-04 and due to reach its primary completion in 2026-08-31. Interventions recorded: YL202. Conditions listed: Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07202364
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07202364: https://clinicaltrials.gov/study/NCT07202364

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [YL202](https://onco.cc/drugs/yl202/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07202364.json